Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Future directions with taxane therapy.

F Cabral1, E Trimble, E Reed

  • 1Department of Integrative Biology, Pharmacology and Physiology, University of Texas Medical School, Houston, USA.

Hematology/Oncology Clinics of North America
|March 18, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated assessment of the effects of PFOA exposure on hepatic transcriptome and lipid profiles in mice expressing human PPARα.

Toxicology and applied pharmacology·2025
Same author

Complete pathological response (pCR) in gastroesophageal cancer: Correlation with metabolic response.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2020
Same author

A new mechanism for void-cascade interaction from nondestructive depth-resolved atomic-scale measurements of ion irradiation-induced defects in Fe.

Science advances·2020
Same author

Initial clinical experience with a powered circular stapler for colorectal anastomosis.

Techniques in coloproctology·2020
Same author

Multi-level Determinants of Clinic Attendance and Antiretroviral Treatment Adherence Among Fishermen Living with HIV/AIDS in Communities on Lake Victoria, Uganda.

AIDS and behavior·2018
Same author

Collaborations in gynecologic oncology education and research in low- and middle- income countries: Current status, barriers and opportunities.

Gynecologic oncology reports·2018
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

This article explores how cancer cells develop resistance to taxanes, a class of chemotherapy drugs. It also reviews taxane use in gynecologic oncology, focusing on dosage and administration.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Taxanes are crucial chemotherapeutic agents used in gynecologic oncology.
  • Understanding drug resistance mechanisms is vital for improving treatment efficacy.

Purpose of the Study:

  • To discuss the biochemical and genetic mechanisms of taxane resistance in cancer cells.
  • To review the clinical application of taxanes in gynecologic oncology, including pharmacokinetic considerations.

Main Methods:

  • Literature review of biochemical and genetic mechanisms of drug resistance.
  • Analysis of pharmacokinetic data related to taxane administration in gynecologic cancer patients.

Main Results:

  • Identified potential biochemical pathways contributing to taxane insensitivity.

Related Experiment Videos

  • Highlighted the importance of dose intensity and administration duration in taxane therapy.
  • Reviewed current clinical practices for taxane utilization in gynecologic oncology.

    • Conclusions:

    • Decreased sensitivity to taxanes can arise from specific cellular mechanisms.
    • Optimizing taxane pharmacokinetics is essential for effective gynecologic cancer treatment.